The $58 million investment has resulted in a 72,000-square-foot facility with a dedicated LC–MS space and molecular suites and will bring as many as 350 new jobs onto the campus.
Patrick Lavery
Advertisement
Patrick Lavery is an Editor for the MJH Life Sciences brands Pharmaceutical Technology and BioPharm International, and their respective websites, pharmtech.com and biopharminternational.com. Previously at MJH, he filled the same role for LCGC International and Spectroscopy.
Articles by Patrick Lavery
Yimmugo, which was introduced in Europe at the end of 2022, could be on the market in the US within months.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration
3
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
4
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
5
